Form 4: Vistagen Therapeutics CEO Shawn Singh Reports Stock Purchase and Disposal
SEC Form 4
CEO Shawn Singh reports purchasing and disposing of Vistagen Therapeutics (VTGN) stock on June 28, 2024, according to a Form 4 filing.
Summary
- On June 28, 2024, Shawn Singh, the CEO of Vistagen Therapeutics, engaged in transactions involving the company's common stock.
- Singh acquired 4,854 shares of common stock at a price of $2.958 per share through the company's Employee Stock Purchase Plan.
- Singh also disposed of 10,487 shares.
- Following these transactions, Singh directly owns 10,487 shares and indirectly owns 20,875 shares through The 1997 Singh Family Trust U/R/D 05/29/97.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions. The purchase is mildly positive, while the disposal is mildly negative, balancing each other out.
Positives
- The purchase of shares by the CEO through the Employee Stock Purchase Plan could be seen as a positive signal.
Negatives
- The disposal of 10,487 shares by the CEO could be interpreted negatively by investors.
Risks
- The document does not explicitly mention any risks.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.
Stakeholder Impact
- Shareholders may react to the reported stock transactions by the CEO.
Key Dates
| Date | Description |
|---|---|
| 05/29/1997 | Date of The 1997 Singh Family Trust U/R/D |
| 06/28/2024 | Date of stock purchase and disposal transactions |
| 07/02/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.